(Yicai) Nov. 16 -- China’s National Healthcare Security Administration has included Tofersen, the world’s first drug for amyotrophic lateral sclerosis caused by SOD1 gene mutations, developed by US pharmaceutical giant Biogen, on its innovative medicine list for commercial insurance coverage. Approved by the National Medical Products Administration in September 2024, Tofersen hit the Chinese market in June 2025, priced at CNY1.4 million (USD209,870) per year.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Wu
Contact Wu, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack